Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

About this update from Contineum Therapeutics, Inc.

SAN DIEGO, March 12, 2025 --( BUSINESS WIRE )--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18 th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250312676311/en/ Contacts Steve Kunszabo Contineum Therapeutics Senior Director, Investor Relations & Corporate Communications 858-649-1158 [email protected]

View stock analysis, news, and events for Contineum Therapeutics, Inc.